{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:38:38Z","timestamp":1792226318036,"version":"4.4.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.6567","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T15:35:14Z","timestamp":1649432114000},"page":"e226567","source":"Crossref","is-referenced-by-count":45,"title":["Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents"],"prefix":"10.1001","volume":"5","author":[{"given":"Rishi J.","family":"Desai","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay R.","family":"Varma","sequence":"additional","affiliation":[{"name":"Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gerhard","sequence":"additional","affiliation":[{"name":"Center for Pharmacoepidemiology and Treatment Science, Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Segal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mufaddal","family":"Mahesri","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristyn","family":"Chin","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Horton","sequence":"additional","affiliation":[{"name":"Center for Pharmacoepidemiology and Treatment Science, Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoung C.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav","family":"Thambisetty","sequence":"additional","affiliation":[{"name":"Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"issue":"4","key":"zoi220209r1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures.","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"zoi220209r2","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines7040097","article-title":"Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research.","volume":"7","author":"Yiannopoulou","year":"2019","journal-title":"Biomedicines"},{"issue":"19","key":"zoi220209r3","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","article-title":"Alzheimer disease in the United States (2010-2050) estimated using the 2010 census.","volume":"80","author":"Hebert","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"zoi220209r4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","article-title":"Therapeutic strategies for Alzheimer\u2019s disease in clinical trials.","volume":"68","author":"Godyn","year":"2016","journal-title":"Pharmacol Rep"},{"issue":"4","key":"zoi220209r5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.bcp.2014.01.002","article-title":"Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles.","volume":"88","author":"Iqbal","year":"2014","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"zoi220209r6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/YCO.0000000000000041","article-title":"Is there still any hope for amyloid-based immunotherapy for Alzheimer\u2019s disease?","volume":"27","author":"Panza","year":"2014","journal-title":"Curr Opin Psychiatry"},{"issue":"12","key":"zoi220209r7","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","article-title":"Neuropathology of older persons without cognitive impairment from two community-based studies.","volume":"66","author":"Bennett","year":"2006","journal-title":"Neurology"},{"issue":"4","key":"zoi220209r8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.bcp.2014.01.009","article-title":"The complexities of the pathology-pathogenesis relationship in Alzheimer disease.","volume":"88","author":"Castellani","year":"2014","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"zoi220209r9","article-title":"Targeting abnormal metabolism in Alzheimer\u2019s disease: the Drug Repurposing for Effective Alzheimer\u2019s Medicines (DREAM) study.","volume":"6","author":"Desai","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"zoi220209r10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations.","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"zoi220209r11","doi-asserted-by":"publisher","first-page":"C353","DOI":"10.1152\/ajpcell.00111.2017","article-title":"Understanding mechanisms and seeking cures for Alzheimer\u2019s disease: why we must be \u201cextraordinarily diverse.\u201d","volume":"313","author":"Thambisetty","year":"2017","journal-title":"Am J Physiol Cell Physiol"},{"issue":"8","key":"zoi220209r12","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jval.2017.08.3019","article-title":"Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.","volume":"20","author":"Berger","year":"2017","journal-title":"Value Health"},{"issue":"7378","key":"zoi220209r13","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/bmj.325.7378.1437","article-title":"Data dredging, bias, or confounding.","volume":"325","author":"Smith","year":"2002","journal-title":"BMJ"},{"issue":"4","key":"zoi220209r14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3233\/JAD-2009-1099","article-title":"The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited.","volume":"17","author":"Taylor","year":"2009","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"zoi220209r15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jalz.2013.03.004","article-title":"Validity of dementia and Alzheimer\u2019s disease diagnoses in Finnish national registers.","volume":"10","author":"Solomon","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"9","key":"zoi220209r16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1474-4422(06)70537-3","article-title":"Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study.","volume":"5","author":"Kivipelto","year":"2006","journal-title":"Lancet Neurol"},{"issue":"6","key":"zoi220209r17","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jalz.2013.11.006","article-title":"Development and validation of a brief dementia screening indicator for primary care.","volume":"10","author":"Barnes","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"11","key":"zoi220209r18","first-page":"1138","article-title":"Predicting diagnosis of Alzheimer\u2019s disease and related dementias using administrative claims.","volume":"24","author":"Albrecht","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"zoi220209r19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/aje\/kwm070","article-title":"Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect.","volume":"166","author":"Brookhart","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"9","key":"zoi220209r20","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/aje\/154.9.854","article-title":"Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.","volume":"154","author":"Schneeweiss","year":"2001","journal-title":"Am J Epidemiol"},{"issue":"7","key":"zoi220209r21","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index.","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"zoi220209r22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects.","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"zoi220209r23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/pds.3263","article-title":"One-to-many propensity score matching in cohort studies.","volume":"21","author":"Rassen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"zoi220209r24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/bimj.v51:1","article-title":"Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations.","volume":"51","author":"Austin","year":"2009","journal-title":"Biom J"},{"key":"zoi220209r25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/CER.S40357","article-title":"Tool for assessing the feasibility of comparative effectiveness research.","volume":"3","author":"Walker","year":"2013","journal-title":"Comp Effect Res"},{"issue":"10","key":"zoi220209r26","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects.","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"issue":"6","key":"zoi220209r27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks.","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"zoi220209r28","article-title":"The puzzle of sex, gender and Alzheimer\u2019s disease: why are women more often affected than men?","volume":"14","author":"Andrew","year":"2018","journal-title":"Womens Health (Lond)"},{"issue":"1","key":"zoi220209r29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1161\/CIRCRESAHA.118.313563","article-title":"Getting to the heart of Alzheimer disease.","volume":"124","author":"Tublin","year":"2019","journal-title":"Circ Res"},{"issue":"1","key":"zoi220209r30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12916-020-01578-x","article-title":"Risk prediction models for dementia: role of age and cardiometabolic risk factors.","volume":"18","author":"Fayosse","year":"2020","journal-title":"BMC Med"},{"issue":"3","key":"zoi220209r31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.v99.3","article-title":"Transparency and reproducibility of observational cohort studies using large healthcare databases.","volume":"99","author":"Wang","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"zoi220209r32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamainternmed.2017.3919","article-title":"Use of health care databases to support supplemental indications of approved medications.","volume":"178","author":"Fralick","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"12","key":"zoi220209r33","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.2337\/dc19-0069","article-title":"Using Real-world data to predict findings of an ongoing phase IV cardiovascular outcome trial: cardiovascular safety of linagliptin versus glimepiride.","volume":"42","author":"Patorno","year":"2019","journal-title":"Diabetes Care"},{"issue":"11","key":"zoi220209r34","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s40263-016-0374-z","article-title":"Treatment for rheumatoid arthritis and risk of Alzheimer\u2019s disease: a nested case-control analysis.","volume":"30","author":"Chou","year":"2016","journal-title":"CNS Drugs"},{"issue":"3","key":"zoi220209r35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229819","article-title":"Tumor necrosis factor (TNF) blocking agents are associated with lower risk for Alzheimer\u2019s disease in patients with rheumatoid arthritis and psoriasis.","volume":"15","author":"Zhou","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"zoi220209r36","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs.","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"8","key":"zoi220209r37","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/pds.1926","article-title":"A basic study design for expedited safety signal evaluation based on electronic healthcare data.","volume":"19","author":"Schneeweiss","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"zoi220209r38","doi-asserted-by":"crossref","first-page":"i5826","DOI":"10.1136\/bmj.i5826","article-title":"Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses.","volume":"355","author":"Wallach","year":"2016","journal-title":"BMJ"},{"key":"zoi220209r39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ejphar.2015.06.060","article-title":"Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.","volume":"764","author":"Fukuyama","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"zoi220209r40","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s13311-016-0471-1","article-title":"Interleukin-6 blockade as rescue therapy in autoimmune encephalitis.","volume":"13","author":"Dale","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"4","key":"zoi220209r41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2014.38","article-title":"Microglial priming in neurodegenerative disease.","volume":"10","author":"Perry","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"zoi220209r42","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.neuroimage.2012.06.055","article-title":"Endotoxin-induced systemic inflammation activates microglia: [11C]PBR28 positron emission tomography in nonhuman primates.","volume":"63","author":"Hannestad","year":"2012","journal-title":"Neuroimage"},{"issue":"21","key":"zoi220209r43","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1212\/WNL.0000000000001617","article-title":"Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial.","volume":"84","author":"Butchart","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"zoi220209r44","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies.","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"zoi220209r45","article-title":"Treatment with TNF-a inhibitors versus methotrexate and the association with dementia and Alzheimer\u2019s disease.","volume":"7","author":"Kern","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"zoi220209r46","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2174\/156720507781788873","article-title":"TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets.","volume":"4","author":"Tweedie","year":"2007","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"zoi220209r47","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3233\/JAD-200711","article-title":"Therapeutic potential of TNF-a inhibition for Alzheimer\u2019s disease prevention.","volume":"78","author":"Torres-Acosta","year":"2020","journal-title":"J Alzheimers Dis"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2790901\/desai_2022_oi_220209_1648733759.94656.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T15:35:24Z","timestamp":1649432124000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2790901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.6567","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]}}}